Opinions Jim Cramer - Mad Money
Anavex Life SciencesAVXLRISKYNov 16, 2022
A clinical-stage biopharma that's trying to apply precision medicine to various nervous system diseases, a tough section of diseases to cure. Their lead drug aims to treat Alzheimer's and Parkinson's. Shares have tripled in recent years on positive data. But shares started to decline a year ago on unprofitable growth stocks like this. Shares have doubled since May due to positive clinical trial data. He doesn't recommend unprofitable companies, but that is the cost of business for early-stage biotech companies. He likes parts of this, but can't recommend this yet, and prefers a surer thing, Eli Lilly. A spec buy.
Jim Cramer - Mad MoneyUnknown
$13.75
Stock price when the opinion was issued
$2.46
As of Jun 10, 2026. Market Open.
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
